The prion protein (PrPC) is a central player in neurodegenerative diseases, such as prion diseases or Alzheimer's disease. In contrast to disease-promoting cell surface PrPC, extracellular fragments act neuroprotective by blocking neurotoxic disease-associated protein conformers. Fittingly, PrPC release by the metalloprotease ADAM10 represents a protective mechanism. We used biochemical, cell biological, morphological, and structural methods to investigate mechanisms stimulating this proteolytic shedding. Shed PrP negatively correlates with prion conversion and is markedly redistributed in murine brain in the presence of prion deposits or amyloid plaques, indicating a sequestrating activity. PrP-directed ligands cause structural changes in PrPC and increased shedding in cells and organotypic brain slice cultures. As an exception, some PrP-directed antibodies targeting repetitive epitopes do not cause shedding but surface clustering, endocytosis, and degradation of PrPC. Both mechanisms may contribute to beneficial actions described for PrP-directed ligands and pave the way for new therapeutic strategies against currently incurable neurodegenerative diseases.

Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies / Linsenmeier, Luise; Mohammadi, Behnam; Shafiq, Mohsin; Frontzek, Karl; Bär, Julia; Shrivastava, Amulya N; Damme, Markus; Song, Feizhi; Schwarz, Alexander; Da Vela, Stefano; Massignan, Tania; Jung, Sebastian; Correia, Angela; Schmitz, Matthias; Puig, Berta; Hornemann, Simone; Zerr, Inga; Tatzelt, Jörg; Biasini, Emiliano; Saftig, Paul; Schweizer, Michaela; Svergun, Dmitri; Amin, Ladan; Mazzola, Federica; Varani, Luca; Thapa, Simrika; Gilch, Sabine; Schätzl, Hermann; Harris, David A; Triller, Antoine; Mikhaylova, Marina; Aguzzi, Adriano; Altmeppen, Hermann C; Glatzel, Markus. - In: SCIENCE ADVANCES. - ISSN 2375-2548. - 7:48(2021), pp. 1-22. [10.1126/sciadv.abj1826]

Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies

Massignan, Tania;Biasini, Emiliano;
2021-01-01

Abstract

The prion protein (PrPC) is a central player in neurodegenerative diseases, such as prion diseases or Alzheimer's disease. In contrast to disease-promoting cell surface PrPC, extracellular fragments act neuroprotective by blocking neurotoxic disease-associated protein conformers. Fittingly, PrPC release by the metalloprotease ADAM10 represents a protective mechanism. We used biochemical, cell biological, morphological, and structural methods to investigate mechanisms stimulating this proteolytic shedding. Shed PrP negatively correlates with prion conversion and is markedly redistributed in murine brain in the presence of prion deposits or amyloid plaques, indicating a sequestrating activity. PrP-directed ligands cause structural changes in PrPC and increased shedding in cells and organotypic brain slice cultures. As an exception, some PrP-directed antibodies targeting repetitive epitopes do not cause shedding but surface clustering, endocytosis, and degradation of PrPC. Both mechanisms may contribute to beneficial actions described for PrP-directed ligands and pave the way for new therapeutic strategies against currently incurable neurodegenerative diseases.
2021
48
Linsenmeier, Luise; Mohammadi, Behnam; Shafiq, Mohsin; Frontzek, Karl; Bär, Julia; Shrivastava, Amulya N; Damme, Markus; Song, Feizhi; Schwarz, Alexander; Da Vela, Stefano; Massignan, Tania; Jung, Sebastian; Correia, Angela; Schmitz, Matthias; Puig, Berta; Hornemann, Simone; Zerr, Inga; Tatzelt, Jörg; Biasini, Emiliano; Saftig, Paul; Schweizer, Michaela; Svergun, Dmitri; Amin, Ladan; Mazzola, Federica; Varani, Luca; Thapa, Simrika; Gilch, Sabine; Schätzl, Hermann; Harris, David A; Triller, Antoine; Mikhaylova, Marina; Aguzzi, Adriano; Altmeppen, Hermann C; Glatzel, Markus
Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies / Linsenmeier, Luise; Mohammadi, Behnam; Shafiq, Mohsin; Frontzek, Karl; Bär, Julia; Shrivastava, Amulya N; Damme, Markus; Song, Feizhi; Schwarz, Alexander; Da Vela, Stefano; Massignan, Tania; Jung, Sebastian; Correia, Angela; Schmitz, Matthias; Puig, Berta; Hornemann, Simone; Zerr, Inga; Tatzelt, Jörg; Biasini, Emiliano; Saftig, Paul; Schweizer, Michaela; Svergun, Dmitri; Amin, Ladan; Mazzola, Federica; Varani, Luca; Thapa, Simrika; Gilch, Sabine; Schätzl, Hermann; Harris, David A; Triller, Antoine; Mikhaylova, Marina; Aguzzi, Adriano; Altmeppen, Hermann C; Glatzel, Markus. - In: SCIENCE ADVANCES. - ISSN 2375-2548. - 7:48(2021), pp. 1-22. [10.1126/sciadv.abj1826]
File in questo prodotto:
File Dimensione Formato  
sciadv.abj1826.pdf

accesso aperto

Tipologia: Post-print referato (Refereed author’s manuscript)
Licenza: Creative commons
Dimensione 4.15 MB
Formato Adobe PDF
4.15 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/374861
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 12
social impact